Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Non-Current Receivables (2019 - 2025)

Historic Non-Current Receivables for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $7.3 million.

  • ImmunityBio's Non-Current Receivables rose 353.76% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 353.76%. This contributed to the annual value of $7.1 million for FY2024, which is 333.33% up from last year.
  • Latest data reveals that ImmunityBio reported Non-Current Receivables of $7.3 million as of Q3 2025, which was up 353.76% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Non-Current Receivables ranged from a high of $7.3 million in Q3 2025 and a low of $6.2 million during Q1 2021
  • Moreover, its 5-year median value for Non-Current Receivables was $6.8 million (2023), whereas its average is $6.8 million.
  • Per our database at Business Quant, ImmunityBio's Non-Current Receivables surged by 442.16% in 2021 and then skyrocketed by 333.33% in 2024.
  • ImmunityBio's Non-Current Receivables (Quarter) stood at $6.4 million in 2021, then increased by 3.58% to $6.6 million in 2022, then grew by 4.09% to $6.9 million in 2023, then rose by 3.33% to $7.1 million in 2024, then rose by 2.62% to $7.3 million in 2025.
  • Its Non-Current Receivables was $7.3 million in Q3 2025, compared to $7.3 million in Q2 2025 and $7.2 million in Q1 2025.